BioSpace News Archive

Forecast to 2030,’ thoroughly examines the Metastatic Prostate Cancer industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Intermittent Claudication industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Chagas Disease industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Angioedema industry to provide essential data & information for the targeted readers.

Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC (“Slayback”), to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations.

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 58,075 shares of its common stock to 25 newly-hired employees, with a grant date of July 26, 2022.

, the U.S. Food and Drug Administration is providing an update on its multipronged response to monkeypox in the United States, including its efforts in the areas of diagnostics, vaccines and therapeutics.

Adicet Bio, Inc., a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, announced it granted inducement awards on July 29, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to seven individuals hired by Adicet in July 2022.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close.

HanAll Biopharma (KRX: 009420.KS), a global biopharmaceutical company focusing on delivering breakthrough therapies for patients, reported financial results for the second quarter 2022 as well as an update to its R&D progress.